The first large-scale efficacy trial of an HIV/AIDS vaccine was conducted by a US company, Vaxgen Co., in which a genetically engineered surface envelope (Env) glycoprotein, gp120, vaccine was tested in humans. This evidence concerns the gene ITIH4 and AIDS.